Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
09:22am, Thursday, 26'th Jan 2023
Things aren't as bad as they might seem.
3 Top-Rated Profitable Stocks to Buy Using Net Income Ratio
07:32am, Thursday, 26'th Jan 2023
Lamb Weston (LW), Pinduoduo (PDD), and Catalyst Pharmaceuticals (CPRX) have been selected as the top picks with a high net income ratio.
Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More
03:53pm, Wednesday, 25'th Jan 2023 Zacks Investment Research
Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
01:03pm, Wednesday, 25'th Jan 2023 GlobeNewswire Inc.
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
07:54am, Wednesday, 25'th Jan 2023 Zacks Investment Research
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
04:31am, Wednesday, 25'th Jan 2023
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic
05:26pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
08:03pm, Monday, 23'rd Jan 2023 Benzinga
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday.
The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. Th
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
06:44pm, Monday, 23'rd Jan 2023 Benzinga
Gainers
Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its biose
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
06:25pm, Monday, 23'rd Jan 2023 GlobeNewswire Inc.
Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE®
3 Reasons Growth Investors Will Love Catalyst (CPRX)
05:45pm, Monday, 23'rd Jan 2023 Zacks Investment Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Dow Jumps Over 300 Points; Crude Oil Up 1%
05:11pm, Monday, 23'rd Jan 2023 Benzinga
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday.
The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500 a
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
04:36pm, Monday, 23'rd Jan 2023 Benzinga
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) shares
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views
03:06pm, Monday, 23'rd Jan 2023 Benzinga
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.
Following the market opening Monday, the Dow traded up 0.11% to 33,411.62 while the NASDAQ
3 Reasons Growth Investors Will Love Catalyst (CPRX)
02:18pm, Monday, 23'rd Jan 2023
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
